Traditional toxicology approaches rely heavily on animal testing, which limits throughput and human relevance. Recent advances in microphysiological system (MPS) platforms allow multiple human organ models to be linked to provide toxicokinetic data while reducing reliance on in vivo studies. The kinetic, metabolism and toxicity data from MPS models can used to build quantitative models designed to improve generation risk assessment (NGRA).
In this webinar, James McKim and Kaushal Joshi will discuss a study evaluating a model compound in an integrated intestine–liver–kidney MPS, highlighting how in vitro ADMET data align with in vivo reports.
Topics to be covered:
The need for new toxicological methods, particularly for repeated dose toxicity
Design and use of a simulated blood flow system to connect multiple organ compartments
Determining fluid volumes and tissue mass to support multiple timepoint sampling
Application of MPS platforms as new approach methodologies to enhance NGRA
Presenters
Drug Discovery News Webinars
James McKim, PhD, DABT
General Manager and Executive Director, In Vitro Assay Services, LifeNet Health
James McKim is a General Manager and Executive Director at LifeNet Health, focusing on developing lab-based alternatives to animal testing. He founded biotech companies CeeTox and IONTOX, where he developed multi-organ systems for evaluating chemical and drug safety. His work includes multiple patents on new approach methodologies and publications in toxicology and safety assessment.
Kaushal Joshi, PhD, DABT
Principal Scientist, Research Institute for Fragrance Materials
Kaushal Joshi is the Principal Scientist at the Research Institute for Fragrance Materials (RIFM), with expertise in non-animal safety testing methods. Since joining RIFM in 2016, he has focused on repeated-dose, reproductive, and computational toxicology, advancing predictive approaches to fragrance and chemical safety. He became a board-certified toxicologist in 2023.